File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Evolution of systemic therapy of advanced hepatocellular carcinoma

TitleEvolution of systemic therapy of advanced hepatocellular carcinoma
Authors
Yau, TChan, PEpstein, RPoon, RT
KeywordsAdvanced hepatocellular carcinoma
Chemotherapy
Doxorubicin
Sorafenib
Issue Date2008
PublisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm
Citation
World Journal Of Gastroenterology, 2008, v. 14 n. 42, p. 6437-6441 How to Cite?
DOI: http://dx.doi.org/10.3748/wjg.14.6437
AbstractHepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC. © 2008 The WJG Press. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/59192
ISSN
1007-9327
2021 Impact Factor: 5.374
2020 SCImago Journal Rankings: 1.427
PubMed Central ID
PMC2773326
ISI Accession Number ID
WOS:000261227200001
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorEpstein, Ren_HK
dc.contributor.authorPoon, RTen_HK
dc.date.accessioned2010-05-31T03:44:46Z-
dc.date.available2010-05-31T03:44:46Z-
dc.date.issued2008en_HK
dc.identifier.citationWorld Journal Of Gastroenterology, 2008, v. 14 n. 42, p. 6437-6441en_HK
dc.identifier.issn1007-9327en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59192-
dc.description.abstractHepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC. © 2008 The WJG Press. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htmen_HK
dc.relation.ispartofWorld Journal of Gastroenterologyen_HK
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAdvanced hepatocellular carcinomaen_HK
dc.subjectChemotherapyen_HK
dc.subjectDoxorubicinen_HK
dc.subjectSorafeniben_HK
dc.subject.meshAntineoplastic Agents - therapeutic use-
dc.subject.meshCarcinoma, Hepatocellular - drug therapy - mortality - pathology-
dc.subject.meshImmunologic Factors - therapeutic use-
dc.subject.meshLiver Neoplasms - drug therapy - pathology-
dc.subject.meshThalidomide - therapeutic use-
dc.titleEvolution of systemic therapy of advanced hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailEpstein, R: repstein@hku.hken_HK
dc.identifier.emailPoon, RT: poontp@hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityEpstein, R=rp00501en_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3748/wjg.14.6437en_HK
dc.identifier.pmid19030192-
dc.identifier.pmcidPMC2773326-
dc.identifier.scopuseid_2-s2.0-63449111025en_HK
dc.identifier.hkuros167035en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-63449111025&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue42en_HK
dc.identifier.spage6437en_HK
dc.identifier.epage6441en_HK
dc.identifier.isiWOS:000261227200001-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridEpstein, R=34975074500en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK
dc.identifier.issnl1007-9327-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats